| Is your age greater than or equal to 18 yrs? |
|
|
|
| Gender: Male or Female |
|
|
|
| Do you have Carcinoma of the Oesophagus? |
|
|
|
| Histologically confirmed adenocarcinoma or squamous cell carcinoma of the oesophagus including Siewert type 1 or 2 tumours with 2cm gastric mucosal extension |
|
|
|
| Unsuitable for radical chemoradiation therapy but suitable for radiotherapy |
|
|
|
| Total length of tumour and involved lymph nodes 10cm |
|
|
|
| No oesophageal stent in situ |
|
|
|
| No previous chemotherapy or radiotherapy for oesophagus cancer |
|
|
|
| Disease which can be encompassed within a radical radiotherapy treatment volume |
|
|
|
| Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (see ECOG criteria appendix 1) |
|
|
|
| Provision of fully informed consent, signed, written and dated, prior to any study specific procedures |
|
|
|
| > 18 years of age |
|
|
|
| Adequate organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below |
|
|
|
| Haemoglobin 10.0 g/dL |
|
|
|
| Absolute neutrophil count (ANC) 1.5 x 109/L |
|
|
|
| White blood cells (WBC) > 3 x 109/L |
|
|
|
| Platelet count 100 x 109/L |
|
|
|
| No dysplastic features on peripheral blood smear |
|
|
|
| Total bilirubin 1.5 x institutional upper limit of normal |
|
|
|
| Aspartate aminotransferase (AST(SGOT)/Alanine transaminase (ALT)SGPT) 2.5 x institutional upper limit of normal |
|
|
|
| Serum creatinine 1.5 x institutional upper limit of normal (ULN) |
|
|
|
| Adequate lung function: no history of interstitial lung disease and FEV1 > 1litre and >30% predicted |
|
|
|
| Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. Postmenopausal is defined as |
|
|
|
| Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments |
|
|
|
| Luteinizing hormone(LH) and Follicle-stimulating hormone (FSH) levels in the post menopausal range for women under 50 |
|
|
|
| radiation-induced oophorectomy with last menses >1 year ago |
|
|
|
| chemotherapy-induced menopause with >1 year interval since last menses |
|
|
|
| surgical sterilisation (bilateral oophorectomy or hysterectomy) |
|
|
|
| Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations |
|
|
|
| Fit to receive all study treatments |
|
|
|
| Swallowing sufficiently good to tolerate oral medication |
|
|
|
| Life expectancy 4 months |
|
|
|
| Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) |
|
|
|
| Previous enrolment in the present study |
|
|
|
| Treatment with any investigational product during the last 14 days (or a longer period depending on the defined characteristics of the agents used) |
|
|
|
| Any previous treatment with a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, including olaparib |
|
|
|
| Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for 5 years |
|
|
|
| Patients receiving the following classes of inhibitors of cytochrome P450 3A4 (CYP3A4) |
|
|
|
| Azole antifungals |
|
|
|
| Macrolide antibiotics |
|
|
|
| Protease inhibitors |
|
|
|
| Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery |
|
|
|
| Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, or any psychiatric disorder that prohibits obtaining informed consent |
|
|
|
| Patients with a history of interstitial lung disease, inflammatory lung conditions, or severe chronic obstructive pulmonary disease (COPD) (FEV1<1litre or < 30% predicted). Patients with pneumonia within the previous 3 months |
|
|
|
| Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication |
|
|
|
| Patients with oesophageal stent in-situ |
|
|
|
| Patients with myelodysplastic syndrome/acute myeloid leukaemia |
|
|
|
| Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) |
|
|
|
| Patients with known active hepatic disease (i.e., Hepatitis B or C) |
|
|
|
| Patients with a known hypersensitivity to olaparib or any of the excipients of the product |
|
|
|
| Patients with uncontrolled seizures |
|
|
|
| Concurrent uncontrolled medical illness, or other previous or current malignant disease likely to interfere with protocol treatments / comparisons |
|
|
|
| Age < 18 |
|
|
|
| Any pregnant, lactating women or potentially childbearing patients not using adequate contraception (see section 3.4 for details of required contraception) |
|
|
|
| Previous chemotherapy or radiotherapy for oesophageal cancer |
|
|
|
| Metastatic disease apart from local lymph node disease which can be reasonably encompassed within the radiotherapy volume (total length of tumour and lymph node disease should be <10cm) |
|
|
|
| ECOG performance status >2 |
|
|
|